MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.

Abstract

TPS11111 Background: While many targeted agents are approved for specific cancers, molecular profiling has increasingly led to the identification of genetic abnormalities in tumor types for which t...